Zhang Jiahui, Zheng Shengkai, Xie Ruiwang, Zhang Junsi, Chen Xiangjin, Xu Sunwang
Department of Thyroid and Breast Surgery, the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Department of Thyroid and Breast Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China.
Cell Death Discov. 2025 Aug 17;11(1):387. doi: 10.1038/s41420-025-02688-2.
Epigenetic regulation plays a key role in the progression, proliferation, and dedifferentiation of thyroid cancer. Epigenetic control occurs at multiple levels, including DNA methylation, RNA modification, histone modification, chromatin remodeling, and chromatin accessibility. Genetic alterations in chromatin regulators are commonly observed in thyroid cancer, which includes papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), anaplastic thyroid carcinoma (ATC), and follicular thyroid carcinoma (FTC). These cancers exhibit distinct characteristics in terms of genetics, biology, and clinical presentation. Therefore, we review the disease biology driven by changes in chromatin pathways in thyroid cancer. Specifically, we summarize examples of epigenetic dysregulation at each level, with mechanisms involving alterations in enzymes regulating DNA methylation, RNA modification and posttranslational modifications of histones, as well as the loss or fusion of subunits involved in chromatin remodeling and chromatin accessibility. Finally, on the basis of clinical applications, we review the current and potential future approaches for thyroid cancer treatment.
表观遗传调控在甲状腺癌的进展、增殖和去分化过程中起着关键作用。表观遗传控制发生在多个层面,包括DNA甲基化、RNA修饰、组蛋白修饰、染色质重塑和染色质可及性。染色质调节因子的基因改变在甲状腺癌中普遍存在,甲状腺癌包括乳头状甲状腺癌(PTC)、髓样甲状腺癌(MTC)、间变性甲状腺癌(ATC)和滤泡状甲状腺癌(FTC)。这些癌症在遗传学、生物学和临床表现方面具有不同的特征。因此,我们综述了甲状腺癌中由染色质途径变化驱动的疾病生物学。具体而言,我们总结了每个层面表观遗传失调的例子,其机制涉及调节DNA甲基化、RNA修饰和组蛋白翻译后修饰的酶的改变,以及参与染色质重塑和染色质可及性的亚基的缺失或融合。最后,基于临床应用,我们综述了甲状腺癌治疗的当前及潜在的未来方法。